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ABSTRACT: 
Fluorescent glucose sensing technologies have been identified as possible alternatives to current continuous glucose 
monitoring approaches. We have recently introduced a new, smart fluorescent ligand to overcome the traditional 
problems of ConA-based glucose sensors.  For this assay to be translated into a continuous glucose monitoring device 
where both components are free in solution, the molecular weight of the smart fluorescent ligand must be increased.  We 
have identified ovalbumin as a naturally-occurring glycoprotein that could serve as the core-component of a 2nd 
generation smart fluorescent ligand.  It has a single asparagine residue that is capable of displaying an N-linked glycan 
and a similar isoelectric point to ConA.  Thus, binding between ConA and ovalbumin can potentially be monovalent and 
sugar specific.  This work is the preliminary implementation of fluorescently-labeled ovalbumin in the ConA-based 
assay.  We conjugate the red-emitting, long-lifetime azadioxatriangulenium (ADOTA+) dye to ovalbumin, as ADOTA 
have many advantageous properties to track the equilibrium binding of the assay.  The ADOTA-labeled ovalbumin is 
paired with Alexa Fluor 647-labeled ConA to create a Förster Resonance Energy Transfer (FRET) assay that is glucose 
dependent. The assay responds across the physiologically relevant glucose range (0-500 mg/dL) with increasing intensity 
from the ADOTA-ovalbumin, showing that the strategy may allow for the translation of the smart fluorescent ligand 
concept into a continuous glucose monitoring device. 
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INTRODUCTION 
Diabetes is a disease that is characterized by blood glucose concentrations that are consistently above normal, due to 
HLWKHUWKHLQDELOLW\RIWKHSDWLHQW¶VSDQFUHDWLFLVOHWFHOOVWRPDNHLQVXOLQ7\SHRUWKHUHVLVWDQFHRIWKHLUFHOOVWRUHVpond 
to insulin (Type 2).  More than 300 million people worldwide currently have diabetes, and those numbers are expected to 
rise.1 The elevated glucose concentrations increase the degree of non-enzymatic protein glycation and, as a result, cause 
secondary complications in the liver, heart, and kidney. 
 In 1993, the Diabetes Control and Complications Trial reported 10 years of clinical data that showed that strict 
management of glucose concentrations within normal levels minimizes these complications. 2 This included the frequent 
measurement of blood sugar concentrations and the appropriate intervention (diet, exercise, medication, and insulin).  
Approximately 10% of the diabetic population has Type 1 diabetes, which can be successfully controlled with the 
administration of insulin.  The rest of the diabetic population has Type 2 diabetes, which primarily relies on the other 
interventions to control their blood sugar.  Diabetes is often diagnosed by a glycated hemoglobin percentage (HbA1c) 
value of greater than 7%.3  Uncontrolled diabetes typically shows an AbA1c value of at least 9%, corresponding to an 
estimated average glucose of ~212 mg/dL.2  On average, if the patient can decrease their eAG by 30 mg/dL, they 
decrease the risk of developing secondary complications by 40%.  The American Diabetes Association (ADA) suggests 
that the target set for most diabetic patients should be an HbA1c value of 7% (corresponding to an eAG of 154 mg/dL). 3  
The primary method of measuring the blood sugar is via the blood glucose meter, and it is recommended that patients 
make 7 glucose measurements per day.  However, 60% of Type 1 diabetic patients average less than a single reading per 
day.4  Continuous glucose monitors (CGM) offer the patient more information and open the possibility for improved 
glycemic control.  While current commercially available CGM primarily can be used in an open-loop system, CGM 
devices are expected to be instrumental in the development of the closed-ORRSJOXFRVHFRQWURONQRZQDV WKHµDUWLILFLDO
SDQFUHDV¶7KLVFORVHG-loop control is expected to have a major impact on the treatment of Type 1 diabetes.5 
The current, commercially-available continuous glucose monitoring devices all use the electrochemical enzymatic 
approach.  These 1st generation enzymatic sensors rely on oxygen diffusion.  This enzymatic based system consumes the 
glucose, and the byproducts are detected by the electrode. 6   This type of chemistry has shown to be accurate and 
repeatable during in vitro tests. However, it requires frequent calibrations for accurate predictions when inserted 
underneath the skin in the percutaneous approach.  Because the sensor measures the byproducts from the oxygen-
mediated glucose consumption, it is highly sensitive to the foreign body response of the host.  This host response 
changes the glucose and oxygen transport from the interstitial fluid to the sensor and shifts the reported values by the 
sensor.  Even with calibrations, current sensors must be replaced after 3-7 days.7 
A large research effort is put towards  finding alternative continuous glucose monitoring sensors that may avoid some of 
these drawbacks to the traditional approach.8  One approach is an affinity-based assay that transduces the signal via 
fluorescence.9 Our group has pursued an affinity-based sensing system that has paired the glucose and mannose binding 
lectin, Concanavalin A (ConA), with a high-affinity fluorescent ligand to which it binds.10-15  The binding of ConA to the 
fluorescent ligand can be engineered to respond to increasing concentrations of glucose, and this can be tracked via 
fluorescence with either anisotropy or energy transfer.  This assay has traditionally shown problems with irreversibility 
and precipitation.16-18 However, we have recently overcome these obstacles in free solution by introducing a smart 
fluorescent ligand.  7KLVVPDUWIOXRUHVFHQWOLJDQGGLVSOD\VDVLQJOHPRLHW\WKDWFDQELQGWR&RQ$¶VIXOOELQGLQJVLWH
(2) is negatively charged, and (3) is fluorescently labeled.19  An obstacle remains for this strategy to be used in a 
continuous glucose sensor: the size of this smart fluorescent ligand must be increased to prevent leaching from the semi-
permeable membrane that allows for glucose diffusion. 
In this work we present a preliminary study that introduces ovalbumin (the primary protein in egg-white) as the high-
affinity fluorescent ligand in a ConA-based glucose sensing assay.  Ovalbumin has been identified as a possible 2nd 
generation smart fluorescent ligand as: (1) it has a single glycosylation site that can present a high-mannose glycan, (2) it 
is negatively charged at physiological pH (with an isoelectric point of 4.5), (3) it has a molecular weight of 45 kD, and 
(4) it has numerous lysine residues that can be labeled with an amine-reactive fluorophore.  This preliminary study uses 
the Azadioxatriangulenium (ADOTA+) fluorophore as ADOTA+ has fluorescence properties ideal for tracking the 
binding between ovalbumin and ConA.20-22 ADOTA+ displays excitation and emission maxima at 540 nm/560 nm with a 
fluorescence lifetime of ~23 ns.  It has moderate brightness with a molar extinction coefficient of 9,800 cm-1M-1 and a 
quantum yield of 0.49 (determined in acetonitrile), with an intrinsic anisotropy has been shown to be 0.38.23,24  
Therefore, ADOTA+ can allow binding studies between relatively large molecules to be tracked with anisotropy,25 and it 
can be used to avoid the shorter fluorescence lifetimes that are common for endogenous fluorophores.26  Figure 1 shows 
a schematic of the energy transfer from the ADOTA-labeled glycated ovalbumin to the Alexa Fluor 647-labeled ConA. 
 
 
Figure 1: Schematic of the energy transfer from the ADOTA fluorophore (red triangle)  to the AF647 fluorophore  (black triangle) 
upon binding of the ovalbumin (light gray) to the ConA (dark gray tetramer) via the single N-linked glycan (green).   
 
MATERIALS & METHODS 
Alexa Fluor 647-labeled Concanavalin A (AF647-ConA) was purchased from Invitrogen (Grand Island, NY).  
Ovalbumin, mannose, TRIS buffer, NaCl, MnCl2, CaCl2, sodium bicarbonate, DMSO, were purchased from Sigma (St. 
Louis, MO) and used as received.  The ADOTA-NHS was received from Dr. Thomas Just Sørensen and Dr.  Bo W 
Laursen (København, Dk).24-26  TRIS buffer was prepared to be 0.01 M TRIS, 0.15 M NaCl, 0.001 M MnCl2, 0.001 M 
CaCl2, pH 7.4.   
The ConA-based assay, as we present it, tracks the fluorescence intensity from the fluorescently-labeled ovalbumin.  As 
a result, it is essential that all of the ovalbumin can bind to ConA.  If a portion of the fluorescently labeled ovalbumin 
cannot bind to ConA, it will serve as a background signal that is not sensitive to glucose concentration and will increase 
the error of the sensor.  The glycans on proteins can display a significant amount of variation, and a large fraction of 
proteins that can be glycated do not actually display glycans.  
We separated the glycated fraction from the non-glycated fraction of our ovalbumin sample by performing affinity-
chromatography with ConA-functionalized resin.  The protein elution from the column was tracked by monitoring the 
absorbance at 280 nm.  After the non-glycated fraction eluted from the column, high concentrations of mannose were 
used to elute the glycated fraction.  This glycated fraction was collected and dialyzed in sodium bicarbonate buffer to 
prepare the sample for labeling.   
This glycated fraction of the ovalbumin was labeled with the ADOTA-NHS using traditional amine-reactive protocol.  
Briefly, ADOTA-NHS was dissolved in DMSO, added dropwise to the solution of glycated ovalbumin in sodium 
bicarbonate buffer (pH 9 to deprotonate the primary amines), mixed well, and allowed to react for 1 hour in the dark at 
room temperature.  Afterwards, the free dye was removed via dialysis against TRIS buffer, and the solution was filtered 
with syringe filters.  UV/VIS absorbance measurements were performed in TRIS buffer.  Using the molar extinction 
coefficients, the concentration and degree of labeling of the ADOTA-ovalbumin was determined.  Similar UV/VIS 
studies were performed with the AF647-ConA that was purchased from Invitrogen.  Characteristic excitation and 
emission spectra are shown in Figure 2. 
 
 
Figure 2: Excitation/Emission spectra of ADOTA+ and AF 647 in TRIS.  The dashed horizontal line -indicates the spectral overlap 
which is required for energy transfer. 
 
The assay was chosen to have 500 nM ADOTA-ovalbumin and 1 ȝ0 AF647-ConA, and was loaded into a cuvette of 
TRIS buffer.  Highly concentrated glucose aliquots were added to minimize dilution effects.  Upon each addition, the 
solutions were mixed well and given time to equilibrate.  At each glucose concentration (0 mg/dL-500 mg/dL)), the 
steady-state fluorescence was measured on a Fluorolog 3.  Excitation was at 500 nm with a 10 nm bandwidth.  Emission 
was collected from 530 nm to 750 nm with a 5 nm bandwidth.   
 
RESULTS & DISCUSSION 
The degree of labeling of the ADOTA-ovalbumin was determined to be approximately 1.5 ADOTA fluorophores per 
glycated ovalbumin.  The degree of labeling of the AF647-ConA was determined to be approximately 3 AF 647 
fluorophores per ConA.    
The assay displayed glucose-dependent fluorescence spectra that are characteristic of competitive binding (Figure 3a).  
The fluorescence of the ADOTA-ovalbumin increased with increasing concentration, indicating that the concentration of 
ADOTA-ovalbumin undergoing FRET (bound population) was decreasing.  The emission of each fluorophore is 
sufficiently separated to minimize the effect that the changing fluorescence intensity of ADOTA has on the AF 647 
fluorescence.  The ratio of the donor to acceptor maxima (560 nm to 670 nm) as a function of glucose concentration is 
shown in Figure 3b.  This shows that the fluorescence of this ADOTA-ovalbumin and AF 647 ConA assay primarily 
changes from 0-300 mg/dL, and then begins to flatten out.  The primary region of interest for physiological glucose 
sensing is 40 mg/dL to 400 mg/dL  
 
 
Figure 3: The fluorescence glucose response of an assay comprised of 500 nM ADOTA-ovalbumin and  
1 ȝ0 AF647-ConA. 
 
Improvements could potentially be made on the assay by increasing the degree of labeling on ConA and performing site-
specific labeling on the ovalbumin with the ADOTA+ fluorophore.  Both of these strategies could improve the average 
FRET efficiency of the bound ovalbumin population.   
 
CONCLUSION 
This work introduces the naturally-occurring protein, ovalbumin, as the core-component of a 2nd generation smart 
fluorescent ligand to be paired with ConA in a fluorescence glucose sensor.  The glycated fraction of ovalbumin was 
separated with affinity chromatography and labeled with the long-fluorescence-lifetime ADOTA+ dye to allow the 
binding to be tracked via fluorescence.   A Förster Resonance Energy Transfer assay was generated by pairing ADOTA-
ovalbumin with AF647-ConA that showed a fluorescence response across physiologically relevant glucose 
concentrations.  This preliminary work indicates that the ADOTA-ovalbumin fluorescent ligand could potentially allow 
the translation of the smart fluorescent ligand concept into a continuous glucose monitoring device. 
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